In this study, we have identified three surface markers in BCC—LYPD3, TACSTD2, and LY6D—that reliably define the nMRTF BCC cell state and can be used as prognostic markers for resistance to SMOi and responsiveness to AP-1 inhibitors. The gene discussed is LYPD3; the disease is skin basal cell carcinoma.